The ESC Textbook of Thrombosis

Raffaele De Caterina is Professor of Cardiology at the University of Pisa, and Director, University Cardiology Division, at Pisa University Hospital. He is also Scientific Advisor for the "G. Monasterio" Foundation, Pisa, Italy. He has been Vice-President of the European Society of Cardiology (2008-2010) and President (2009-2013) of the International Society on Nutrigenetics/Nutrigenomics. He is the past-Editor-in-Chief of the journal Vascular Pharmacology, curent Executive Editor of European Heart Journal, and author of >600 peer-reviewed manuscripts. Major research interests: Cardiovascular Pharmacology, Atrial Fibrillation, Coronary Artery Disease, Cardiovascular Thrombosis, Nutrigenetics and Nutrigenomics. David J. Moliterno, MD (FESC, FACC, FSCAI, FAHA) is a Professor at the University of Kentucky. He was an attending cardiologist at the Cleveland Clinic for 10 years before joining the University of Kentucky, where he was chief of cardiovascular medicine and subsequently chair of internal medicine. Dr. Moliterno has been a visiting professor or lecturer in more than 30 countries. He is the author of over 400 publications and editor of 8 textbooks. He has been the primary author of publications in BMJ, Circulation, EHJ, JACC, JAMA, Lancet, and NEJM. He is currently the Editor-in-Chief for the JACC: Cardiovascular Interventions and serves on the advisory board of the US FDA. As a clinical researcher, Dr. Moliterno has been a leader in numerous multinational investigational studies. Collectively, these studies have involved over $1 billion in clinical trial research. His primary interests involve acute coronary syndromes, antithrombotic therapies, and interventional cardiology. Steen Dalby Kristensen is a professor and interventional cardiologist at Aarhus University Hospital, Denmark. Scientific/clinical interests: Thrombosis and anti-thrombotic treatment. Coronary artery disease and acute cardiac care. Percutaneous coronary interventions. Author of more than 365 scientific papers and 17 book chapters. Editor of 5 textbooks. Editor of European Heart Journal, Thrombosis and Haemostasis and European Heart Journal: Acute Cardiovascular Care. Invited speaker in more than 40 different countries. Supervisor of 15 PhD students. Chair of international research committees for evaluation of scientific applications in Germany and Spain. Evaluator of grants in Sweden, Norway, Italy, Germany, Spain, Finland and Denmark. Has been ESC Vice-president, ESC secretary/treasurer and leader of several key ESC initiatives, ESC committees and working groups. Past President of the Danish Society of Cardiology

1: Raffaele De Caterina, David J. Moliterno, and Steen Dalby Kristensen: Introduction
Section 1: Pathophysiology of thrombosis
2: Lina Badimon and Gemma Vilahur: Arterial thrombosis: Pathophysiological background
3: Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van Es: Venous thrombosis and thromboembolism: Pathophysiological background
4: Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip: Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background
5: Tobias Geisler: Thrombosis on foreign surfaces and devices
Section 2: Clinical pharmacology of antithrombotic drugs
6: Carlo Patrono and Bianca Rocca: Aspirin
7: Manan Pareek and Deepak L. Bhatt: Platelet P2Y12 inhibitors
8: Luis Ortega-Paz and Dominick Angiolillo: Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists
9: Renske Olie and Hugo ten Cate: Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid
10: Freek W.A. Verheugt and Marc Brouwer: Vitamin K antagonists
11: Alex Benz and Stefan Hohnloser: Dabigatran
12: Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan Wallen: Oral factor Xa (FXa) inhibitors
13: James C. Fredenburgh and Jeffrey I. Weitz: Forthcoming oral factor XIa and FXIIa inhibitors
14: Peter R Sinnaeve and Frans Van de Werf: Thrombolytic therapy and ancillary antithrombotic therapies
Section 3: Therapeutic strategies
15: Raffaele De Caterina, Paul M Ridker, and Erica Michelotti: Antithrombotic strategies in primary cardiovascular prevention
16: Antonio Greco and Davide Capodanno: Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions
17: William A. E. Parker, Raffaele De Caterina, David J. Moliterno, Steen Dalby Kristensen and Robert F. Storey: Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes
18: Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno: Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions
19: Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom: Antithrombotic therapies in ischaemic stroke
20: Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and Erik Lerkevang Grove: Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis
21: Raffaele De Caterina and Rossella Marcucci: Atrial fibrillation: current and forthcoming antithrombotic therapies
22: Chaozer Er, Walter Ageno, and Ander Cohen: Venous thromboembolism: prophylaxis and treatment
23: Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbäck: Biomarker-based risk stratification in cardiovascular disease
Section 4: Special situations
24: Vittorio Pengo and Gentian Denas: Antithrombotic therapies in inherited or acquired thrombophilia
25: Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao: Prevention and treatment of bleeding related to antithrombotic drug treatment
26: Michael Maeng, Steen Dalby Kristensen, and Jolanta M. Siller-Matula: Management of patients treated with antithrombotic drugs undergoing surgery
27: Alexander C Fanaroff, Renato D Lopes, John H Alexander: Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome
28: Stefan Agewall, Vanessa Roldán, and Francisco Marín: Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy
29: Steven P. Dunn, Craig J. Beavers, and David J. Moliterno: Antithrombotic agents and drug-drug interactions
30: Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and Konstantinos D. Rizas: Personalised antithrombotic therapy: Measuring individual variation and monitoring
31: Serge Korjian, Yazan Daaboul, and C. Michael Gibson: Drug development, clinical trials, and regulatory requirements